Back

Comparative effectiveness and safety of edoxaban vs warfarin in patients with atrial fibrillation: a nationwide cohort study

28 August 2021 (07:51 - 08:00)
Organised by:
Congress Presentation Part of: Atrial fibrillation: risks and management Epidemiology, Prognosis, Outcome ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Mr Peter Bronnum Nielsen

Aalborg University, Aalborg (Denmark)

4 More presentations in this session

Presentation thumbnail
Risk of dementia according to smoking cessation after newly diagnosed atrial fibrillation: a nationwide cohort study
Doctor H. Lee (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Beta-blocker treatment in atrial fibrillation with chronic obstructive pulmonary disease: a Danish nationwide study from 1995 to 2015
Mr C. Benson (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study
Doctor S. Lee (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Chronic kidney disease and risk of atrial fibrillation and heart failure in general population-based cohorts - the BiomarCaRE project.
Professor D. Rothenbacher (Ulm, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation: risks and management

The Event

Event poster

ESC Congress 2021 - The Digital Experience

28 August 2021 07:51 CET
You may be interested in
thumbnail
Congress Presentation
Comparison of warfarin, dabigatran, rivaroxaban and apixaban for effectiveness and safety among elderly patients with atrial fibrillation: a nationwide cohort study
31 August 2020
thumbnail
Congress Session
From clinical trials to clinical practice: long-term effectiveness and safety of anticoagulation in patients with atrial fibrillation
27 August 2023
thumbnail
Congress Presentation
Edoxaban monitoring strategy using chromogenic anti-Xa assays among patients with atrial fibrillation
3 April 2025
thumbnail
Congress Presentation
Cost-effectiveness of oral anticoagulant therapy in patients with device-detected atrial fibrillation
12 April 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources